Which ASX ETFs hold Cytokinetics Inc (CYTK)?
As at Q3 2026, CYTK is among the most widely held stocks across ASX-listed ETFs, appearing in approximately 3 ETFs. Its largest single position is approximately 1.03% in CURE (Global X S&P Biotech ETF). General information only, not financial advice.
General information only, not financial advice. ETFLens does not hold an AFSL. Always read the relevant PDS and consider seeking advice from a licensed financial adviser.
All weights are approximate, drawn from each fund's published holdings as at Q3 2026, and change as funds rebalance.
| ETF | Fund | Category | Weight |
|---|---|---|---|
| CURE | Global X S&P Biotech ETF | Thematic | approx. 1.03% |
| VISM | Vanguard MSCI International Small Companies Index ETF | Global Broad Market | approx. 0.09% |
| VTS | Vanguard US Total Market Shares Index ETF | US Shares | approx. 0.01% |
Want to see what any of these funds overlap with? Try the free ETF overlap checker, or browse the most widely held stocks.
Hold more than one of these? See your combined CYTK exposure across all your ETFs with the Stock X-Ray.
CYTK in ETFs: frequently asked questions
Which ASX ETFs hold CYTK?
Cytokinetics Inc (CYTK) is held by approximately 3 ASX-listed ETFs, including CURE, VISM, VTS. General information only.
Which ETF has the largest CYTK weighting?
CURE (Global X S&P Biotech ETF) has the largest CYTK position at approximately 1.03% of the fund, as at Q3 2026. Past weightings are not a reliable indicator of future weightings.